Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide

Cancer Research

Volumn 63, Issue 14, 2003, Pages 4112-4118

  Nakahara, Saori ^a   Tsunoda, Takuya ^a   Baba, Toshiyuki ^a   Asabe, Shinichi ^b   Tahara, Hideaki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 INTEGRIN; CARCINOEMBRYONIC ANTIGEN; CD83 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; PEPTIDE; PICIBANIL; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOPHENOTYPING; MOUSE; NONHUMAN; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; STREPTOCOCCUS PYOGENES; TH1 CELL; TUMOR IMMUNITY; TUMOR REJECTION; VACCINATION;

ANTIGENS, CD18; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-12; MEMBRANE GLYCOPROTEINS; PICIBANIL; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS;

EID: 0041672399     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Englemam, E. G., and Levy, R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med., 2: 52-58, 1996.
2. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med., 4: 328-332, 1998.
3. Murphy, G. P., Tjoa, B. A., Simmons, S. J., Ragde, H., Rogers, M., Elgamal, A., Kenny, G. M., Troychak, M. J., Salgaller, M. L., and Boynton, A. L. Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate, 39: 54-59, 1999.
4. Reichardt, V. L., Okada, C. Y., Liso, A., Benike, C. J., Stockerl-Golgstein, K. E., Engleman, E. G., Blume, K. G., and Levy, R. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: a feasible study. Blood, 93: 2411-2419, 1999.
5. Murphy, G. P., Tjoa, B. A., Simmons, S. J., Jarisch, J., Bowes, V. A., Ragde, H., Rogers, M., Elgamal, A., Kenny, G. M., Cobb, O. E., Ireton, R. C., Troychak, M. J., Salgaller, M. L., and Boynton, A. L. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a Phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate, 38: 73-78, 1999.
6. Simmons, S. J., Tjoa, B. A., Rogers, M., Elgamal, A., Kenny, G. M., Ragde, H., Troychak, M. J., Boynton, A. L., and Murphy, G. P. GM-CSF as a systemic adjuvant in a Phase II prostate cancer vaccine trial. Prostate, 39: 291-297, 1999.
7. Lim, S. H., and Bailey-Wood. R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int. J. Cancer, 83: 215-222, 1999.
8. Thurner, B., Haendle, I., Röder. C., Dickmann, D., Keikavoussi, P., Jonuleit, H., Bender, A., Maczek, C., Schreiner, D., von den Driesch, P., Bröcker, E. B., Steinman, R. M., Enk, A., Kämpgen, E., and Schuler, G. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med., 190: 1669-1678, 1999.
9. Rieser, C., Ramoner, R., Holtl, R., Rogatsch, H. L., Papesh, C., Stenzl, A., Bartsch, G., and Thurnher, M. Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma. Urol. Int., 63: 151-159, 1999.
10. Panelli, M. C., Wunderlich, J., Jeffries, J., Wang, E., Mixon, A., Rosenberg, S. A., and Marincola, F. M. Phase I study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J. Immunother., 23: 487-498, 2000.
11. + melanoma patients by mature monocyte-derived dendritic cells. J. Immunol., 165: 3492-3496, 2000.
12. Chaperot, L., Chokri, M., Jacob, M. C., Drillat, P., Garban, F., Egelhofer, H., Molens, J. P., Scotto, J. J., Bensa, J. C., and Plumas, J. Differentiation of antigen-presenting cells (dendritic cells and macrophages) for therapeutic application in patients with lymphoma. Leukemia (Baltimore), 14: 1667-1677, 2000.
13. Toungouz, M., Libin, M., Bulte, F., Faid, L., Lehmann, F., Duriau, D., Laporte, M., Gangji, D., Bruyns, C., Lambermont, M., Goldman, M., and Velu, T. Transient expansion of peptide-specific lymphocytes producing IFN-γ after vaccination with dendritic cells pulsed with MAGE peptides in patients with MAGE-A1/A3-positive tumors. J. Leukocyte Biol., 69: 937-943, 2001.
14. Fong, L., Brockstedt, D., Benike, C., Wu, L., and Engleman, E. G. Dendritic cells injected via different routes induce immunity in cancer patients. J. Immunol., 66: 4254-4259, 2001.
15. Sinkovics, J. G., and Horvath, J. C. Vaccination against human cancers. Int. J. Oncol., 16: 81-96, 2000.
16. Dhodapkar, M., Steinman, R. M., Krasovsky, J., Munz, C., and Bhardwaj, N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med., 193: 233-238, 2001.
17. Banchereau, J., and Steinman, R. M. Dendritic cells and the control of immunity. Nature (Lond.), 392: 245-252, 1998.
18. + dendritic cells. Proc. Natl. Acad. Sci. USA, 93: 2588-2592, 1996.
19. Romani, N., Reider, D., Heuer, M., Ebner, S., Kämpgen, E., Eibl, B., Niederwieser, D., and Schuler, G. Generation of mature dendritic cells from human blood an improved method with special regard to clinical applicability. J. Immunol. Methods. 196: 137-151, 1996.
20. Bender, A., Sapp, M., Schuler, G., Steinman, R. M., and Bhardwaj, N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J. Immunol. Methods, 196: 121-135, 1996.
21. Jonuleit, H., Kuhn, U., Muller, G., Steinbrink, K., Paragnik, L., Schmitt, E., Knop, L., and Enk, A. H. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol., 27: 3135-3142, 1997.
22. Winzler, C., Rovere, P., Rescigno, M., Granucci, F., Penna, G., Adorini, L., Zimmermann, V. S., Davoust, J., and Ricciardi-Castagnoli, P. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J. Exp. Med., 185: 317-328, 1997.
23. Sallusto, F., Cella, M., Danieli, C., and Lanzavecchia, A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med., 182: 389-400, 1995.
24. Fujimoto, T., Duda, R. B., Szilvasi, A., Chen, X., Mai, M., and O'Donnell, M. A. Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state. J. Immunol., 158: 5619-5626, 1997.
25. + T cells into the tumor sites and synergistically induce the local production of Th1-type cytokines and CXC3 chemokines. Cancer Immunol. Immunother., 49: 361-368, 2000.
26. Sallusto, F., and Lanzaveccia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med., 179: 1109-1118, 1994.
27. Nukaya, I., Yasumoto, M., Iwasaki, T., Ideno, M., Sette, A., Celis, E., Tekesako, K., and Kato, I. Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. Int. J. Cancer, 80: 92-97, 1999.
28. Tsunoda, T., Tanimura, H., Yamaue, H., Tanaka, H., and Matsuda, K. Tumor specific CTL therapy for advanced cancer and development for cancer vaccine. Hepatogastroenterology, 46: 1287-1292, 1999.
29. Celis, E., Tsai, V., Crimi, C., DeMars, R., Wentworth, A. P., Chesnut, W. R., Grey, M. H., Sette, A., and Serra, M. H. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. Natl. Acad. Sci. USA, 91: 2105-2109, 1994.
30. Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., and Davis, M. M. Phenotypic analysis of antigen-specific T lymphocytes. Science (Wash. DC), 274: 94-96, 1996.
31. Romero, P., Dunbar, P. R., Valmori, D., Pittet, M., Ogg, G. S., Rimoldi, D., Chen, J-L., Liénard, D., Cerottini, J-C., and Cerundolo, V. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med., 188: 1641-1650, 1998.
32. Bodinier, M., Peyrat, M. A., Tournay, C., Davodeau, F., Romagne, F., Bonneville, M., and Lang, F. Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding. Nat. Med., 6: 707-710, 2000.
33. Palacios, R., and Steinmetz, M. IL-3 dependent mouse clones that express B-220 surface antigen contain Ig genes in germ-line configuration, and generate lymphocytes in vivo. Cell, 41: 727-734, 1985.
34. Fujita, T., Nolan, G. P., Liou, H. C., Scott, M. L., and Baltimore, D. The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-κB p50 homodimers. Genes Dev., 7: 1354-1363, 1993.
35. Flo, T. H., Halaas, Ø. Lien, E., Ryan, L., Teti, G., Golenbock, D. T., Sundan, A., and Espevik, T. Human toll-like receptor 2 mediates monocyte activation by Listeria monocytogenes, but not by Group B Streptococci or lipopolysaccharide. J. Immunol., 164: 2064-2069, 2000.
36. Shimazu, R., Akashi, S., Ogata, H., Nagai, Y., Furudome, K., Miyake, K., and Kimoto, M. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J. Exp. Med., 189: 1777-1782, 1999.
37. Beutler, B. Tlr4: central component of the sole mammalian LPS sensor. Curr. Opin. Immunol., 12: 20-26, 2000.
38. Tapping, R. I., Akashi, S., Miyake, K., Godowski, P. J., Tobias, P. S. Toll-like receptor 4, but not toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides. J. Immunol., 165: 5780-5787, 2000.
39. Takeuchi, O., Hoshino, K., Kawai, K., Sanjo, H., Takada, H., Ogawa, T., Takeda, T., and Akira, S. Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity, 11: 443-451, 1999.
40. Schwandner, R., Dziarski, R., Wesche, H., Rothe, M., and Kirschning, C. J. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J. Biol. Chem., 274: 17406-17409, 1999.
41. Cella, M., Scheidegger, D., Palmer-Lehmann, K., Lane, P., Lanzavecchia, A., and Alber, G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med., 184: 747-752, 1996.
42. Koch, F., Stanzl, U., Jennewein, P., Janke, K., Heufler, C., Kampgen, E., Romani, N., and Schuler, G. F. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med., 184: 741-746, 1996.
43. Sousa, C. R., Hieny, S., Scharton-Kersten, T., Jankovic, D., Charest, H., Germain, R. N., and Sher, A. In vivo microbial stimulation induces rapid CD40L-independent production of IL-12 by dendritic cells and their redistribution to T cell areas. J. Exp. Med., 186: 1819-1829, 1997.
44. Dieu, M. C., Vanbervliet, B., Vicari, A., Bridon, J. M., Oldham, E., Ait-Yahia, S., Briere, F., Zlotnik, A., Lebecque, S., and Caux, C. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. Med., 188: 373-386, 1998.
45. Lemaitre, B., Nicolas, E., Michaut, L., Reichhart, J. M., and Hoffman, J. A. The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell, 86: 973-983, 1996.
46. Mitcham, J. L., Parnet, P., Bonnert, T. P., Garka, K. E., Gerhart, M. J., Slack, J. L., Gayle, M. A., Dower, S. K., and Sims, J. E. T1/ST2 signaling establishes it as a member of an expanding interleukin-1 receptor family. J. Biol. Chem., 271: 5777-5783, 1996.
47. Medzhitov, R., Preston-Hurlburt, P., and Janeway, C. A., Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature (Lond.), 388: 394-397, 1997.
48. Rock, F. L., Hardiman, G., Timans, J. C., Kastelein, R. A., and Bazan, F. A family of human receptors structurally related to Drosophila Toll. Proc. Natl. Acad. Sci. USA, 95: 588-593, 1998.
49. Takeuchi, O., Kawai, T., Sanjo, H., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., Takeda, K., and Akira, S. TLR6: a novel member of an expanding toll-like receptor family. Gene (Amst.), 231: 59-65, 1999.
50. Chaudhary, P. M., Ferguson, C., Nguyen, V., Nguyen, O., Massa, H. F., Eby, M., Jasmin, A., Trask, B. J., Hood, L., and Nelson, P. S. Cloning and characterization of two toll/interleukin-1 receptor-like genes TIL3 and TIL4: evidence fora multi-gene receptor family in humans. Blood, 91: 4020-4027, 1998.
51. Okamoto, M., Oshikawa, T., Ohe, G., Nishikawa, H., Furuichi, S., Tano, T., Morioya, Y., Saito, M., and Sato, M. Severe impairment of anti-cancer effect of lipoteichoic acid-related molecule isolated from a penicillin-killed Streptococcus pyogenes in toll-like receptor 4-deficient mice. Int. Immunopharmacol., 1: 1789-1795, 2001.
52. Okamoto, M., Kaji, R., Kasetani, H., Yoshida, H., Moriya, Y., Saito, M., and Sato, M. Purification and characterization of interferon-γ-inducing molecule of OK-432, a penicillin-killed Streptococcus preparation, by monoclonal antibody neutralizing interferon-γ-inducing activity of OK-432. J. Immunother., 13: 232-242, 1993.
53. Okamoto, M., Gohda, H., Ohe, G., Yoshida, H., Matsuno, T., Saito, M., and Sato, M. Cytokine-inducing activity and antitumor effect of liposome-incorporated interferon-γ-inducing molecule derived from OK-432, a streptococcal preparation. J. Immunother., 23: 94-103, 2000.
54. Okamoto, M., Ohe, G., Oshikawa, T., Nishikawa, H., Furuichi, S., Yoshida, H., Matsuno, T., Saito, M., and Sato, M. Induction of Th1-type cytokines by lipoteichoic acid-related preparation isolated from OK-432, a penicillin-killed streptococcal agent. Immunopharmacology, 49: 363-376, 2000.
55. 2 integrins are involved in cytokine responses to whole Gram-positive bacteria. J. Immunol., 164: 5871-5876.